Bristol Myers Squibb Co. closed 6.82% below its 52-week high of $63.33, which the company reached on March 11th.
In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other Friday’s ...
14h
EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...
Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...
Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback